Ex Vivo Metrics™, a preclinical tool in new drug development

被引:5
|
作者
Curtis, C. Gerald [1 ]
Bilyard, Kevin [2 ]
Stephenson, Hugo
机构
[1] Bowman Res Inc, Des Plaines, IL USA
[2] Nine TZ Healthcare Ventures, Post House, Congleton, Cheshire, England
关键词
Drug Development; Drug Candidate; Human Organ; Translational Medicine; Drug Development Process;
D O I
10.1186/1479-5876-6-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Among the challenges facing translational medicine today is the need for greater productivity and safety during the drug development process. To meet this need, practitioners of translational medicine are developing new technologies that can facilitate decision making during the early stages of drug discovery and clinical development. Ex Vivo Metrics (TM) is an emerging technology that addresses this need by using intact human organs ethically donated for research. After hypothermic storage, the organs are reanimated by blood perfusion, providing physiologically and biochemically stable preparations. In terms of emulating human exposure to drugs, Ex Vivo Metrics is the closest biological system available for clinical trials. Early application of this tool for evaluating drug targeting, efficacy, and toxicity could result in better selection among promising drug candidates, greater drug productivity, and increased safety.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Lubricin as a tool for controlling adhesion in vivo and ex vivo
    Manasa, Clayton S.
    Silva, Saimon M.
    Desroches, Pauline E.
    Dennaoui, Jessair
    Russo, Mathew J.
    Han, Mingyu
    Quigley, Anita F.
    Greene, George W.
    Kapsa, Robert M. I.
    Moulton, Simon E.
    BIOINTERPHASES, 2021, 16 (02)
  • [32] Ex vivo Bone Models and Their Potential in Preclinical Evaluation
    Cramer, E. E. A.
    Ito, K.
    Hofmann, S.
    CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (01) : 75 - 87
  • [33] Ex vivo Bone Models and Their Potential in Preclinical Evaluation
    E. E. A. Cramer
    K. Ito
    S. Hofmann
    Current Osteoporosis Reports, 2021, 19 : 75 - 87
  • [34] New cast for a new era: preclinical cancer drug development revisited
    Herter-Sprie, Grit S.
    Kung, Andrew L.
    Wong, Kwok-Kin
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (09): : 3639 - 3645
  • [35] Establishment of an ex vivo tissue culture model as a potential preclinical drug testing platform for hepatocellular carcinoma
    Feng, Huiche
    Cieri, Miriam
    Esposito, Cinzia
    Guja-Jarosz, Karolina
    Liberati, Daniela
    Bubendorf, Lukas
    Soysal, Savas Deniz
    Coto-Llerena, Mairene
    Terracciano, Luigi Maria
    Kollmar, Otto
    Piscuoglio, Salvatore
    CANCER RESEARCH, 2024, 84 (06)
  • [36] The 1000 cancer phenotype project - a preclinical ex-vivo next generation drug screening platform
    Oppermann, Sina
    Scheinost, Sebastian
    Wagner, Lena
    Walther, Tatjana
    Oles, Malgorzata
    Kim, Vladislav
    Huellein, Jennifer
    Dietrich, Sascha
    Zenz, Thorsten
    Lu, Junyan
    Huber, Wolfgang
    LEUKEMIA & LYMPHOMA, 2017, 58 : 186 - 187
  • [37] Development of an ex vivo preclinical respiratory model of idiopathic pulmonary fibrosis for aerosol regional studies
    Montigaud, Yoann
    Perinel-Ragey, Sophie
    Plantier, Laurent
    Leclerc, Lara
    Goy, Clemence
    Clotagatide, Anthony
    Prevot, Nathalie
    Pourchez, Jeremie
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [38] Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
    Corben, Adriana D.
    Uddin, Mohammad M.
    Crawford, Brooke
    Farooq, Mohammad
    Modi, Shanu
    Gerecitano, John
    Chiosis, Gabriela
    Alpaugh, Mary L.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2014, (92):
  • [39] Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early-Stage Drug Development
    Arnold, Yvonne E.
    Kalia, Yogeshvar N.
    BIOMEDICINES, 2020, 8 (09)
  • [40] Development of an ex vivo preclinical respiratory model of idiopathic pulmonary fibrosis for aerosol regional studies
    Yoann Montigaud
    Sophie Périnel-Ragey
    Laurent Plantier
    Lara Leclerc
    Clémence Goy
    Anthony Clotagatide
    Nathalie Prévôt
    Jérémie Pourchez
    Scientific Reports, 9